Outlook Therapeutics (NASDAQ:OTLK) Earns “Buy” Rating from HC Wainwright

Outlook Therapeutics (NASDAQ:OTLK)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $30.00 price target on the stock.

Several other analysts have also recently weighed in on OTLK. Chardan Capital reaffirmed a “neutral” rating on shares of Outlook Therapeutics in a report on Monday, December 2nd. BTIG Research reduced their price objective on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 29th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $28.07.

Outlook Therapeutics Trading Up 1.8 %

Outlook Therapeutics stock opened at $2.23 on Friday. The firm has a market capitalization of $55.55 million, a P/E ratio of -0.25 and a beta of 0.53. Outlook Therapeutics has a twelve month low of $0.87 and a twelve month high of $12.85. The stock’s fifty day simple moving average is $2.70 and its 200-day simple moving average is $5.34.

Outlook Therapeutics (NASDAQ:OTLK) last issued its quarterly earnings results on Friday, December 27th. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.06. Sell-side analysts predict that Outlook Therapeutics will post -2.33 earnings per share for the current year.

Institutional Trading of Outlook Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. grew its position in shares of Outlook Therapeutics by 55.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 51,459 shares of the company’s stock valued at $275,000 after buying an additional 18,287 shares during the last quarter. State Street Corp boosted its stake in Outlook Therapeutics by 10.0% in the third quarter. State Street Corp now owns 232,542 shares of the company’s stock valued at $1,242,000 after acquiring an additional 21,201 shares in the last quarter. Great Point Partners LLC grew its holdings in shares of Outlook Therapeutics by 15.0% during the second quarter. Great Point Partners LLC now owns 1,701,510 shares of the company’s stock worth $12,557,000 after purchasing an additional 221,510 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Outlook Therapeutics by 49.2% during the third quarter. Geode Capital Management LLC now owns 341,959 shares of the company’s stock worth $1,826,000 after purchasing an additional 112,812 shares in the last quarter. Finally, Barclays PLC lifted its holdings in shares of Outlook Therapeutics by 677.4% in the 3rd quarter. Barclays PLC now owns 20,943 shares of the company’s stock valued at $111,000 after purchasing an additional 18,249 shares during the last quarter. Institutional investors and hedge funds own 11.20% of the company’s stock.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.